The Chinese pharmaceutical company Antengene has started pricing negotiations with the National Health Insurance Service for its multiple myeloma drug ‘Xpovio Tab (Selinexor),’ bringing near its reimbursement listing in Korea.

Xpovio was approved in July 2021 as a treatment for blood cancer. At the time of its approval, it became the first new drug developed by a Chinese pharmaceutical company to be approved by Korea’s Ministry of Food and Drug Safety.

However, it has faced many challenges during the health insurance reimbursement review after its approval.

According to industry sources on the 28th, Antengene recently started drug pricing negotiations with the National